Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 7/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3740314 | 0.81 | TSHR (0.41) | TSHRMAPK1CNR2TNFBCHE | |
| SCHEMBL13041654 | 0.80 | TSHR (0.48) | TSHRMAPK1CNR2BCHEACHE | |
| SCHEMBL3734997 | 0.78 | TSHR (0.40) | TSHRMAPK1CNR2TNFBCHE | |
| SCHEMBL3731195 | 0.74 | BCHE (0.40) | TSHRMAPK1CNR2BCHEACHE | |
| SCHEMBL7887333 | 0.74 | MC4R (0.39) | CNR2BCHEACHEHDAC1 | |
| SCHEMBL3733588 | 0.72 | CNR2 (0.51) | TSHRMAPK1CNR2BCHEACHE | |
| SCHEMBL7745731 | 0.72 | TSHR (0.50) | TSHRMAPK1CNR2BCHEACHE | |
| SCHEMBL6247270 | 0.72 | MAPK1 (0.50) | TSHRMAPK1CNR2BCHEACHE | |
| SCHEMBL6242878 | 0.72 | MAPK1 (0.50) | TSHRMAPK1CNR2BCHEACHE | |
| SCHEMBL6216271 | 0.69 | TSHR (0.47) | TSHRMAPK1CNR2BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | ASTRAZENECA UK LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | RB1, RPP30, SARS1 | TSHR 548/4885MAPK1 2919/4885CNR2 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.